Glofit-GemOx in R/R DLBCL: FDA Advisory Committee Reviews STARGLO Phase 3 Results for Transplant-Ineligible Patients

Source: Pharmacy Times articles

Glofitamab combined with GemOx shows promising survival benefits for patients with relapsed DLBCL, offering a new treatment option for those ineligible for transplants.
Read More